In re Savient Pharmaceuticals, Inc., et al.,

Court Documents and Claims Register
Case No. 13-12680 (MFW)


IMPORTANT DATES

Effective Date - May 30, 2014 Notice of Effective Date of the Plan

On October 14, 2013, Savient Pharmaceuticals, Inc. and its affiliate, Savient Pharma Holdings, Inc. (collectively, the “Debtors”), filed voluntary petitions for relief under chapter 11 of title 11 of the United States Bankruptcy Code (the “Chapter 11 Cases”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”). These Chapter 11 Cases have been assigned to the Honorable Judge Mary F. Walrath. The Debtors are jointly administered under the main case, Savient Pharmaceuticals, Inc., Case No. 13-12680.

On December 13, 2013, Honorable Mary F. Walrath signed an Order authorizing the sale of substantially all the Debtors’ assets free and clear of all liens, claims, encumbrances and interests to Crealta Pharmaceuticals LLC. Savient retained certain personnel to wind-down its operations, ceased conducting ongoing business, and has transitioned substantially all of its assets to Crealta Pharmaceuticals.

On March 18, 2014, a hearing was held at which the Court entered an Order approving the Disclosure Statement of the proposed Chapter 11 Plan of Liquidation. On May 19, 2014 the Bankruptcy Court entered its Findings of Fact, Conclusions of Law, and Order Confirming First Amended Plan of Liquidation Pursuant to Chapter 11 of the Bankruptcy Code Proposed by the Debtors. A copy of the Order is available by clicking here. On May 30, 2014, the Effective Date as defined under the plan occurred. A copy of the related Notice is available by clicking here.

For all questions pertaining to the administration of these Chapter 11 Cases, please contact the Counsel to the Liquidating Trust for Savient Pharmaceuticals, Inc., et al at:

Pachulski Stang Ziehl & Jones LLP
Att: Bradford J. Sandler, Esq.
Attn: Shirley S. Cho, Esq.
919 North Market Street, 17th Floor
Wilmington, Delaware 19801
Telephone (302) 652-4100
Facsimile: (302) 652-4400

Press Releases